Fig. 2.
PRMT6 deficiency enhances antiviral innate immunity in vivo. a Survival of Prmt6+/+ and Prmt6–/– mice after intraperitoneal injection of VSV (1.5 × 108 plaque-forming units per gram of body weight) (n = 7). b Determination of VSV load in the liver, spleen, and lungs of Prmt6+/+ and Prmt6–/– mice 18 h after infection with VSV, as measured by TCID50 assay. c Real-time PCR analysis of VSV RNA levels in liver, spleen, and lungs of Prmt6+/+ and Prmt6–/– mice 18 h after intraperitoneal injection with a medium or VSV. d Hematoxylin-and-eosin staining of lung sections from mice in C. Scale bar, 50 μm. e ELISA demonstrating serum cytokine levels in Prmt6+/+ and Prmt6–/– mice after intraperitoneal injection of VSV for the indicated lengths of time. Data in a and d are representative of three independent experiments. Data in b, c, and e are presented as the mean ± SEM of three independent experiments. *p < 0.05, **p < 0.01